Remarkable Response to 177 Lu-PSMA and 177 Lu-DOTA-IBA Cocktail Therapy in a Patient With Dual Primary Malignancies.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41697713.
- Also identified by DOI 10.1097/RLU.0000000000006380.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A patient with metastatic atypical right lung carcinoid underwent 68 Ga-FAP2286 and 68 Ga-DOTATATE PET/CT scans to assess eligibility for radionuclide therapy, which revealed insufficient coverage of all lesions by either tracer. The imaging also identified a prostate mass with markedly elevated PSA level; biopsy confirmed prostate adenocarcinoma with neuroendocrine differentiation. Subsequent 68 Ga-PSMA PET/CT demonstrated high uptake in all lesions. Guided by these multimodal imaging, the patient received combined 177 Lu-PSMA and 177 Lu-DOTA-IBA therapy. Notably, he achieved near-complete remission of both primary malignancies and all metastases after one cycle of cocktail therapy and one cycle of 177 Lu-DOTA-IBA therapy.
Medical subject headings
- Lutetium
- Organometallic Compounds
- Radioisotopes
- Prostatic Neoplasms
- Lung Neoplasms
- Oligopeptides
- Dipeptides